I have two recent pet peeves. First, vendors sell pharma commercial teams on platforms — Snowflake, Databricks, Tableau, Power BI — and then quietly move on, leaving the actual work of automation, forecasting, and insight delivery to whoever is left holding the bag. Usually one overextended analyst. Second, when lean pharma teams finally realize they need help, the options available to them were designed for someone else entirely.
Over my career I have watched pharma commercial organizations go through the same cycle. They buy the platform. They hire the analyst. They bring in the consultant. Six months later the QBR is still being built in Excel, the forecasting model is still a concept, and the pipeline the contractor built in month two is broken and unowned. The platforms are fine. The options for actually executing on them are not.
This piece is my attempt to name that problem clearly, explain why it happens, and describe what a better model looks like. I do it the way I wish more people would: with concrete examples and without pretending the answer is just “buy more software.”
Why now?
Four things happened in the last few years that made this an urgent problem instead of a manageable one.
Pharma commercial teams were already stretched. Field force reporting, market access analytics, patient journey modeling, payer mix analysis — each of these was already a full-time job. As the data stack grew more sophisticated, so did the gap between what the platforms could theoretically do and what the team actually had time to build.
A dashboard with a fuzzy definition of “script volume” annoys a brand director. An AI agent with the same fuzzy definition writes the territory realignment, ranks the call plan, and files the budget forecast — all based on the wrong number. The cost of a bad data foundation used to be a slow report. Now it is a confident wrong answer delivered at machine speed.
Five years ago a pharma team might have had Veeva and a BI tool. Today the average commercial analytics stack includes a cloud warehouse, a transformation layer, two or three visualization tools, a data science environment, and an alphabet soup of connectors. Each vendor sold the platform. Nobody sold the integration, the automation, or the ownership.
Leadership wants predictive models, real-time dashboards, and AI-powered forecasting. The team has one senior analyst, one data engineer on loan from IT, and a backlog that has not gotten shorter in two years. The ask grew. The team did not.
When the gap between what the stack can do and what the team can execute stays small, you can manage it. When it becomes a chasm — and in pharma commercial analytics, it has — the question is no longer “do we need help” but “why does every form of help we try leave us in the same place?”
Frequently asked questions
Commercial analytics leaders throw around terms like “data strategy,” “execution partner,” “managed services,” and “center of excellence” without much consistency. Teams do not know what to ask for, and the people in the middle — the analytics directors, the VP of commercial ops — are left translating vendor promises into something their CFO will approve.
This piece is the FAQ I keep needing to have before any conversation about pharma data team structure goes anywhere useful. I use two running examples throughout: a mid-sized specialty pharma company trying to get their field force analytics out of Excel, and a lean commercial ops team that has already tried the Big 4, a staffing agency contractor, and two vendor-led implementations. Both show up in nearly every answer.
1. Why do pharma data teams stay stuck despite investing in the right platforms?
The platforms are not the problem. Snowflake is an excellent warehouse. Databricks is a serious data science environment. Tableau and Power BI are mature visualization tools. The teams buying them are not naive. They did the evaluation. They made the right call.
The problem is that a platform is not an outcome. It is the prerequisite for one.
Take the mid-sized specialty pharma company. They modernized their data stack eighteen months ago. Snowflake replaced their legacy data warehouse. Tableau replaced their old BI tool. They brought in a data engineer to build the pipelines. On paper, the infrastructure is sound.
In practice, the field force report still takes three days to produce. The forecasting model is a spreadsheet maintained by one person who is two weeks from leaving for a competitor. The Tableau dashboards exist, but the brand team still exports them to PowerPoint because the filters do not work the way they need. The platform is live. The execution layer never got built.
This is not a technology failure. It is a structural one. Platforms are purchased by procurement. Execution requires people — the right mix of them, organized around a specific problem, accountable for an outcome, not just a deliverable. That combination is exactly what most of the options available to pharma teams do not provide.
A data warehouse without automation is just a very expensive place to store the same manual process. A Tableau license without adoption is just a subscription fee. Every layer of the stack depends on the layer beneath it, and the layer beneath most pharma commercial data stacks is execution — which nobody sold them.
2. What are the three broken options, and why does each one fail the same way?
The lean commercial ops team tried all three. Their experience is instructive not because they made mistakes, but because they did not. They chose the options available to them. The options were the problem.
The Big 4
The engagement started well. Senior people in the room. A structured discovery process. A detailed roadmap with phases and milestones and a governance framework that looked impressive in the deck.
Six months in, the senior people had rotated off. The team doing the work was two years out of school and learning Snowflake on the client’s dime. The deliverable was a strategy document and a recommended org structure. The analyst was still building the QBR in Excel. When the engagement ended, nothing ran without the consultants. Because nothing was ever designed to.
The Contractor
The contractor — placed by a staffing agency, usually on a six- or twelve-month contract — was fast. Within two weeks there was a working Databricks pipeline pulling from three source systems. Within six weeks the model was running. The dashboard was clean. The stakeholders were impressed.
Then the contract ended. Three months later the pipeline broke because one of the source systems changed a schema. Nobody knew how to fix it. The contractor was on another engagement at another company. The documentation was sparse. The model that had been running in production was quietly abandoned, and the team went back to the manual process.
The Vendor
Every platform vendor — Snowflake, Tableau, Databricks — has a professional services arm. The pitch is compelling: who better to implement the platform than the people who built it?
The answer is: almost anyone with a stake in your outcome rather than their renewal. Vendor professional services is designed to drive adoption of the platform. The success metric is platform utilization, not business outcome. If the forecasting model gets built in a way that requires three Databricks clusters and a premium tier upgrade, that is a feature, not a problem. The automation that would let your team run the model without vendor support is not in the implementation scope, because the implementation scope was written by the vendor.
Each option fails the same way, for a different reason. The Big 4 leaves when the engagement ends, and the work does not run without them. The contractor leaves when the contract ends, and the work breaks without them. The vendor stays, but the work stays dependent on them. In every case, the team ends up in the same place: owning infrastructure they cannot fully operate, accountable for outcomes nobody set them up to deliver.
The failure is not incompetence. It is misalignment between what the option was designed to do and what the team actually needs.
3. What does the execution gap actually cost?
This is the question most pharma commercial analytics leaders underestimate, because the cost is distributed and invisible until it is not.
The direct cost is the easiest to see. A senior analyst in pharma commercial runs $120,000 to $160,000 in salary before benefits and overhead. A data engineer with Snowflake and dbt experience runs similarly. Hiring all five roles a lean team actually needs — product owner, data engineer, AI specialist, analyst, architect — through traditional hiring would cost somewhere between $700,000 and $1,000,000 annually, assuming you could find them, hire them, and retain them in a market that is actively competing for all of them.
The indirect cost is harder to quantify and more damaging. It shows up as the forecast that was three weeks late to the brand planning cycle. The territory alignment built on stale data because nobody had time to refresh the model. The executive dashboard the VP of Sales stopped trusting six months ago because the numbers did not match what the field was telling her. The AI initiative that got announced at the national sales meeting and quietly shelved because the data foundation was not ready.
The specialty pharma company that modernized their stack eighteen months ago is not behind because they made bad technology choices. They are behind because the execution layer was never resourced. Every month that passes without it is a month of compounding lag — in insight quality, in model accuracy, in stakeholder trust. The gap does not stay the same size. It grows.
4. What would a model designed for lean teams with enterprise expectations actually look like?
Start with what lean pharma teams actually need, rather than with what existing models happen to offer.
Engineering, analytics, data science, architecture, product ownership — organized around a specific outcome, not a generalist who covers three of the five at a medium level of proficiency.
The pipeline that breaks in month three needs to be owned by someone who remembers building it and has an incentive to fix it. In pharma commercial analytics, where the data environment changes constantly, continuity is the difference between a system that compounds value over time and one that quietly decays.
The billable hour is not compatible with lean team budgets, because the billable hour has no incentive to finish. A fixed-fee, outcome-oriented model aligns the partner’s incentive with the team’s outcome: the faster the work runs without intervention, the better the model works for everyone.
The strategy document that lives on the consultant’s server is not an asset. The pipeline that only the contractor understands is not an asset. What gets built should run inside the team’s own environment, documented well enough that the team can operate it.
Not until the engagement ends. Not until the project scope is delivered. Until the work is actually working. This is not a complicated model. It is just not the model that any of the three existing options provides.
5. How do you know when you have the right partner versus the right-sounding pitch?
Every consulting firm, every staffing agency, and every vendor professional services team will tell you they are different. That they are outcome-oriented. That they stay until it runs. The pitch is not the differentiator. The model is.
Ask four questions before you sign anything.
The specialty pharma company that tried all three options eventually found a model that answered all four questions consistently. The QBR that took three days now runs automatically on Monday morning. The forecasting model is in production and updated monthly. The field force analytics are trusted by the brand team. None of that happened because they bought a better platform. It happened because they found a partner designed for the kind of team they are, not the kind of team the options assumed they were.
Closing
The platforms pharma commercial teams are buying are not the problem. The execution gap between what the platform can do and what the team can deliver is the problem. And the three options currently available to lean teams — the Big 4, the staffing agency contractor, the vendor — each fail in a predictable and structural way, not because the people involved are incompetent, but because none of those models were designed for this team, this problem, or this kind of work.
Naming the problem is the first step. The next is finding a model that was actually built to solve it.
This is the first piece in a series. Future pieces will go deeper on specific topics: how to build a pharma commercial data foundation that AI agents can actually use, what good forecasting infrastructure looks like for a specialty pharma commercial team, and how to know when your data stack is ready for the automation layer versus when you are automating a broken process at higher speed.
One crew. One fixed fee. We don’t leave until it runs.
Rower assembles a dedicated crew around your specific problem — a product owner, data engineer, AI specialist, analyst, and architect — working inside the tools you already have. Tableau, Power BI, Snowflake, Databricks, Alteryx, dbt. Fixed fee. No surprises.
If you can hire one senior analyst, you can afford an entire Rower Crew.
Fixed fee · No hourly billing · Your team owns everything we build
Rower works inside the tools you already have
